Prevalence and Treatment of Drug-Induced Extrapyramidal Symptoms

1978 ◽  
Vol 132 (1) ◽  
pp. 27-30 ◽  
Author(s):  
D. A. W. Johnson
Keyword(s):  
Side Effects ◽  
Prevalence Rate ◽  
Extrapyramidal Symptoms ◽  
Anticholinergic Drugs ◽  
Drug Induced ◽  
Factors Influencing ◽  
Schizophrenic Patients ◽  
Depot Neuroleptic ◽  
Antiparkinsonian Drugs

A prospective follow-up of schizophrenic patients treated with depot neuroleptic injections demonstrated the variability of the prevalence rate of morbidity from drug-induced extrapyramidal symptoms. Factors influencing this morbidity are discussed. This study suggests that the need for the treatment of drug-induced symptoms by the use of antiparkinsonian drugs is less than commonly accepted. It is suggested that our psychological set to the problem of drug-induced side-effects requires revision, and in particular that the prescription of anticholinergic drugs needs justification.

Effectiveness of Clozapine in Hospitalised People with Chronic Neuroleptic-Resistant Schizophrenia

1995 ◽  
Vol 167 (6) ◽  
pp. 760-764 ◽  
Author(s):  
Moshe Avnon ◽  
Jonathan Rabinowitz
Keyword(s):  
Side Effects ◽  
Psychiatric Hospital ◽  
Chronic Schizophrenia ◽  
Schizophrenic Patients ◽  
Chronic Neuroleptic ◽  
Drop Outs

BackgroundClozapine's effectiveness in reducing symptoms and facilitating discharge among patients with chronic schizophrenia who were resistant to neuroleptics was studied.MethodAll 169 such patients in a public psychiatric hospital were given clozapine. BPRS ratings (0–5 scale) were completed before treatment and 21 months later. Patients were followed for about 2.5 years.ResultsClozapine was discontinued in 37.8% of cases due to non-compliance, non-response, or side-effects. At follow-up 41 % of clozapine recipients and 25.9% of the drop-outs were discharged and remained so, and 33% of recipients and 24.1% of drop-outs were being prepared for discharge. Longer treatment was associated with more improvement. Decline in average BPRS total scores of recipients was significantly more than drop-outs (32.7, s.d. 16.8 v. 12.1, s.d. 14.1, d.f. = 155, t = 7.5, P = 0.000).ConclusionsClozapine appears to be effective for treating some chronic neuroleptic non-responding schizophrenic patients.

Neuroleptic Prescription for Chinese Schizophrenics in Hong Kong

1992 ◽  
Vol 26 (2) ◽  
pp. 262-264 ◽  
Author(s):  
Helen Chiu ◽  
Sing Lee ◽  
C.M. Leung ◽  
Y.K. Wing
Keyword(s):  
Hong Kong ◽  
Side Effects ◽  
High Frequency ◽  
Anticholinergic Drugs ◽  
Extrapyramidal Side Effects ◽  
High Potency ◽  
Frequency Of Use ◽  
Daily Dose ◽  
Schizophrenic Patients ◽  
The Mean

There are very few studies on the pattern of neuroleptic prescription for schizophrenics in Asia. 106 schizophrenic patients in a psychiatric unit of a general teaching hospital in Hong Kong were surveyed. The mean daily dose (in chlorpromazine equivalent) was low (568.5mg). The mean daily dose of high potency agents was four times that of low potency agents. A high frequency of use of anticholinergic drugs may indicate that Chinese are more susceptible to acute extrapyramidal side-effects.

Awkward movements: Extrapyramidal symptoms in a group of patients treated with aripiprazole long acting injectable

2016 ◽  
Vol 33 (S1) ◽  
pp. S552-S553
Author(s):  
C. Victor ◽  
S. Berta ◽  
T. Ivan ◽  
O. Silvia ◽  
C. Sandra ◽  
...  
Keyword(s):  
Side Effects ◽  
Oral Treatment ◽  
Care Center ◽  
Extrapyramidal Symptoms ◽  
Average Score ◽  
Health Care Center ◽  
Normal Limits ◽  
Competing Interest ◽  
Long Acting

IntroductionExtrapyramidal symptoms are well known as side effects in therapy with antipsychotics. Explore this side effects is mandatory because they normally are a cause of treatment discontinuation or assess a change in medication. Some studies notice how long acting injectable antipsychotic cause less extrapyramidal symptoms than oral treatment, others does not find differences.ObjectiveThe aim of this study is to analyze the extrapyramidal symptoms presented on a group of patients treated with aripiprazole long acting injectable (ALAI) follow-up in a mental health care center.MethodsDescriptive study of a group of patients treated with ALAI. To assess the possible extrapyramidal symptoms due to treatment we have used the Simpson-Angus Scale (SAS). The follow up was 3 months after initiation of treatment.ResultsSix patients were included in the study, 2 women (33.3%) and 4 men (66.7%). The mean age of the sample was 37 years old. The different diagnoses of the group were 4 patients with psychotic disorder (66.7%; 2 schizophrenia, 1 schizoaffective disorder and 1 delusional chronic disorder) and the other 2 had an affective disorder (33.3%; both bipolar disorder). The average score for the SAS was 1.2 meaning normal results and therefore no significant extrapyramidal symptoms.ConclusionsIn our sample the average of the results obtained by applying the SAS is considered within normal limits. In our case as to extrapyramidal effects ALAI treatment has been well tolerated. A larger sample would be needed to obtain more reliable results.Disclosure of interestThe authors have not supplied their declaration of competing interest.

Antiparkinsonian Drugs in the Treatment of Neuroleptic-Induced Extrapyramidal Symptoms

1994 ◽  
Vol 39 (2) ◽  
pp. 74-84 ◽  
Author(s):  
Kalyna Z. Bezchlibnyk-Butler ◽  
Gary J. Remington
Keyword(s):  
Side Effects ◽  
Mode Of Action ◽  
Extrapyramidal Symptoms ◽  
Clinical Use ◽  
Atypical Neuroleptics ◽  
Neuroleptic Therapy ◽  
Antiparkinsonian Drugs

Most patients on neuroleptic therapy experience extrapyramidal symptoms in one form or another during treatment. While the risk of extrapyramidal symptoms appears diminished with the newer and “atypical” neuroleptics (for example, risperidone, remoxipride, clozapine), it is not eliminated. It is essential that the treating clinician monitor for such side effects since if they are left untreated they can be an ongoing source of discomfort to the patient and may affect compliance with therapy. Antiparkinsonian medication represents the mainstay of treatment for neuroleptic-induced extrapyramidal symptoms. Their clinical use is reviewed here with reference to mode of action, indications, choice, side-effects and precautions.

scholarly journals Using a Discrete Choice Experiment to Examine the Factors Influencing Clinical Trial Participation in a Nationally Representative Sample

2021 ◽  
Author(s):  
Michelle Queally ◽  
Declan Devane ◽  
Matthew D. Griffin ◽  
Paddy Gillespie ◽  
Abhay Pandit
Keyword(s):  
Clinical Trial ◽  
Side Effects ◽  
Discrete Choice ◽  
Choice Experiment ◽  
Financial Incentive ◽  
Relative Importance ◽  
Factors Influencing ◽  
Trade Offs ◽  
Nationally Representative

Abstract IntroductionUnderstanding the key factors that inform an individual’s decision-making process for participating in a clinical trial (CT) can improve the efficiency of recruitment for CT studies. Currently, little is known, in quantitative terms, about the relative importance of the different factors that influence CT participation decisions.ObjectiveThe objectives of this study were to design and conduct a discrete choice experiment (DCE) to identify critical factors, or attributes, that influence CT participation, and to estimate public preferences for, and trade-offs between, different levels of these attributes.MethodsA DCE was designed, with input from a public patient involvement (PPI) panel and conducted via an online survey of 525 nationally representative Irish citizens. The attributes identified and included in the DCE to inform CT participation included: (1) communication, (2) financial incentive, (3) likelihood of benefit, (4) risk of side effects, and (5) follow up period. All respondents were presented with a set of choice cards and asked to choose between participating in one of two CTs, differentiated by their attributes levels, or opt-out. A series of econometric statistical regression models were estimated to generate the results of interest.ResultsRespondents had preferences which, in order of relative importance, had a lower risk of side effects, a higher likelihood of benefit, a shorter follow up, information communicated by the respondent’s doctor or nurse, and a financial incentive for participation.ConclusionTo the best of our knowledge, this is the first study to utilise a DCE to estimate preferences of the public regarding factors influencing CT participation. These findings may be useful for future CT design as they enable researchers to elicit how individuals may weigh up their choices and consider trade-offs between factors that affect their decision to participate. This study was also the first DCE to include a PPI panel to help inform the DCE design and development.

Bilateral Ulnar Nerve Paralysis: An Unreported Complication of Drug-Induced Extrapyramidal Rigidity

1997 ◽  
Vol 31 (3) ◽  
pp. 427-428 ◽  
Author(s):  
Govindarajan Sampath ◽  
Ananda K. Pandurangi
Keyword(s):  
Case Report ◽  
Side Effects ◽  
Ulnar Nerve ◽  
Clinical Picture ◽  
Complete Recovery ◽  
Anticholinergic Medication ◽  
Extrapyramidal Side Effects ◽  
Drug Induced ◽  
Nerve Paralysis ◽  
Depot Neuroleptic

Objective: This case report describes a very unusual consequence of drug-induced extrapyramidal side effects. Clinical picture: The patient developed bilateral ulnar nerve paralysis. Treatment: The treatment consisted of anticholinergic medication and physiotherapy. Outcome: The patient made a complete recovery over a period of 8 months. Conclusions: There is a need to ensure compliance with anticholinergic medication when using depot neuroleptic medication.

Cannabis Consumption as a Prognostic Factor in Schizophrenia

1994 ◽  
Vol 164 (5) ◽  
pp. 679-681 ◽  
Author(s):  
M. J. Martinez-Arevalo ◽  
A. Calcedo-Ordoñez ◽  
J. R. Varo-Prieto
Keyword(s):  
Mental Health ◽  
Prognostic Factor ◽  
Course Of Illness ◽  
Follow Up Study ◽  
Factors Influencing ◽  
Health Centres ◽  
Cannabis Consumption ◽  
Schizophrenic Patients ◽  
One Year

Data were analysed from 62 schizophrenic patients between 18 and 30 years of age, treated at the community mental health centres in Navarra, who had relapsed and then completed a one-year follow-up study. Factors influencing the course of illness during follow-up were: continuing cannabis consumption; previous cannabis intake; non-compliance with treatment; and stress.

A Clinical Trial of the Efficacy and Acceptability of d-Fenfluramine in the Treatment of Neuroleptic-induced Obesity

1988 ◽  
Vol 153 (2) ◽  
pp. 208-213 ◽  
Author(s):  
E. Goodall ◽  
Christine Oxtoby ◽  
Ray Richards ◽  
Gill Watkinson ◽  
David Brown ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Weight Loss ◽  
Side Effects ◽  
Mental State ◽  
Controlled Trial ◽  
Dietary Advice ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Schizophrenic Patients ◽  
Depot Neuroleptic

Twenty-nine overweight schizophrenic patients maintained on depot neuroleptic injections who wished to lose weight took part in a double-blind, placebo-controlled trial of 30 mg d-fenfluramine. All subjects received dietary advice. Sixteen patients completed the 12-week trial. Rate of weight loss was significantly greater in those taking d-fenfluramine. Side-effects were reported, but no deterioration in mental state was noted.

scholarly journals Recommendations for the follow-up of patients with cardiovascular disease when administering potentially effective medications for the treatment of COVID-19 with a purpose to reduce the risk of QT prolongation and sudden cardiac death

2020 ◽  
Vol 26 (2) ◽  
pp. 21-26
Author(s):  
Iskren Garvanski ◽  
Ivo Petrov ◽  
Iana Simova
Keyword(s):  
Cardiovascular Disease ◽  
Side Effects ◽  
Sudden Cardiac Death ◽  
Cardiac Death ◽  
Torsades De Pointes ◽  
Qt Prolongation ◽  
Drug Induced ◽  
Rising Incidence ◽  
Number Of Publications

With the rising incidence and wider spread of the COVID-19 pandemic worldwide, it is of great importance to safely use potentially effective medicines to treat the infection. In recent weeks, a number of publications have emerged describing the likely effect of the use of known drugs, including chloroquine and hydroxychloroquine, and their combination with azithromycin. One of the most serious risks associated with the use of these medications is the drug-induced QT prolongation, which in turn increases the risk of developing torsades de pointes (TdP) and sudden cardiac death (SCD). In this document, we describe an approach to screen patients and monitor them with the aim to reduce the risk of drug-induced side effects.

Sign in / Sign up

Export Citation Format

Share Document